Your browser is no longer supported. Please, upgrade your browser.
Settings
CCXI ChemoCentryx, Inc. daily Stock Chart
CCXI [NASD]
ChemoCentryx, Inc.
Index- P/E51.76 EPS (ttm)0.19 Insider Own4.80% Shs Outstand51.08M Perf Week-0.50%
Market Cap510.29M Forward P/E- EPS next Y-1.17 Insider Trans-75.40% Shs Float30.67M Perf Month9.18%
Income12.50M PEG- EPS next Q-0.25 Inst Own55.60% Short Float4.52% Perf Quarter-4.77%
Sales89.80M P/S5.68 EPS this Y141.80% Inst Trans1.72% Short Ratio5.92 Perf Half Y-19.82%
Book/sh0.43 P/B23.23 EPS next Y-41.00% ROA6.50% Target Price19.75 Perf Year76.19%
Cash/sh3.39 P/C2.95 EPS next 5Y- ROE32.20% 52W Range5.42 - 15.08 Perf YTD67.90%
Dividend- P/FCF14.02 EPS past 5Y18.30% ROI19.60% 52W High-33.55% Beta1.69
Dividend %- Quick Ratio2.90 Sales past 5Y72.40% Gross Margin- 52W Low84.87% ATR0.58
Employees66 Current Ratio2.90 Sales Q/Q0.00% Oper. Margin11.50% RSI (14)46.03 Volatility4.81% 5.43%
OptionableYes Debt/Eq0.68 EPS Q/Q-60.30% Profit Margin13.90% Rel Volume0.89 Prev Close9.99
ShortableYes LT Debt/Eq0.68 EarningsNov 08 AMC Payout0.00% Avg Volume233.96K Price10.02
Recom1.80 SMA20-0.11% SMA50-4.60% SMA200-14.61% Volume195,251 Change0.30%
Sep-07-18Initiated B. Riley FBR Neutral $12.50
Aug-14-18Downgrade JP Morgan Overweight → Neutral
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Initiated H.C. Wainwright Buy $20
Feb-21-17Initiated JMP Securities Mkt Outperform
May-18-15Upgrade JP Morgan Neutral → Overweight
May-20-13Reiterated Stifel Buy $16 → $20
Nov-14-12Initiated Stifel Nicolaus Buy $16
Nov-29-18 04:05PM  ChemoCentryxs Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference GlobeNewswire
Nov-27-18 08:50AM  New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 08:30AM  ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-09-18 01:37AM  Edited Transcript of CCXI earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents -14.10%
Nov-08-18 07:00PM  ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:58PM  ChemoCentryx: 3Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Nov-01-18 08:30AM  ChemoCentryx to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 GlobeNewswire +5.27%
Oct-30-18 10:33AM  Earnings Preview: ChemoCentryx (CCXI) Q3 Earnings Expected to Decline Zacks +9.91%
Oct-25-18 01:30PM  Presentations at ASN Kidney Week 2018 Highlight ChemoCentryx Platform in Treatment of ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Oct-16-18 09:20AM  Analysis: Positioning to Benefit within ChemoCentryx, Armstrong Flooring, Kornit Digital, NewLink Genetics, Silvercorp Metals, and Halcon Resources Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +9.00%
Sep-27-18 10:20PM  ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock GlobeNewswire -18.04%
Sep-26-18 06:28PM  After-hours buzz: BBBY, KRP & more CNBC
04:01PM  ChemoCentryx Announces Proposed Public Offering of Common Stock GlobeNewswire
08:30AM  ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference GlobeNewswire
Sep-18-18 01:03AM  VIFOR PHARMA GROUP INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX GlobeNewswire +9.82%
Aug-28-18 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-27-18 07:55PM  Edited Transcript of CCXI earnings conference call or presentation 9-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-20-18 08:20AM  Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-09-18 07:00PM  ChemoCentryx (CCXI) Reports Q2 Loss, Misses Revenue Estimates Zacks
05:55PM  ChemoCentryx: 2Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Aug-02-18 08:30AM  ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 GlobeNewswire
Jul-13-18 02:24PM  J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit Zacks
Jul-12-18 09:21AM  Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks
Jul-10-18 10:37AM  KemPharm Stock Down Despite Positive Data on ADHD Candidate Zacks
Jul-02-18 10:34AM  Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics Zacks
07:04AM  Zacks.com featured highlights include: Weight Watchers, Johnson Outdoors, ChemoCentryx, Harte-Hanks and IEC Zacks
Jun-29-18 09:59AM  7 Stocks With Recent Price Strength to Enhance Your Returns Zacks -5.79%
09:30AM  Will ChemoCentryx (CCXI) Continue to Surge Higher? Zacks
Jun-22-18 09:53AM  ChemoCentryx, 58.com, Seagate, Garmin and Texas Instruments as Zacks Bull and Bear of the Day Zacks
07:00AM  Bull of the Day: ChemoCentryx (CCXI) Zacks
Jun-14-18 01:15PM  4 Top-Ranked Nasdaq Stocks That Have Doubled This Year InvestorPlace
Jun-06-18 08:54AM  Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5% Zacks
Jun-04-18 08:20AM  Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.94%
May-30-18 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
May-23-18 08:30AM  ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress GlobeNewswire
May-17-18 10:07AM  Can The Uptrend Continue for ChemoCentryx (CCXI)? Zacks
May-16-18 08:00AM  Better Know Biotech: 2 Stocks You Ought to Know About Motley Fool +9.36%
May-14-18 11:51PM  Edited Transcript of CCXI earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-09-18 07:28PM  ChemoCentryx: 1Q Earnings Snapshot Associated Press
04:05PM  ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
May-02-18 08:30AM  ChemoCentryx to Hold First Quarter 2018 Financial Results Conference Call on Wednesday, May 9, 2018 GlobeNewswire
Apr-19-18 07:40AM  Free Research Report as ChemoCentryxs Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y ACCESSWIRE
Apr-12-18 06:07PM  Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio? Simply Wall St.
Apr-11-18 04:05PM  ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting GlobeNewswire
Apr-10-18 07:45AM  Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-04-18 03:43PM  Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry? Simply Wall St. +5.96%
Apr-03-18 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
Apr-02-18 07:40AM  Wired News Exelixis Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX ACCESSWIRE -9.34%
Mar-22-18 08:30AM  ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Mar-11-18 07:05PM  Edited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-10-18 08:22PM  ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript Motley Fool
Mar-09-18 11:22AM  ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven? Simply Wall St. +11.94%
07:41AM  ChemoCentryx posts 4Q profit Associated Press
07:00AM  ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights GlobeNewswire
06:30AM  Chemocentryx, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-18 08:30AM  ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 08:30AM  ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018 GlobeNewswire
Jan-22-18 05:00PM  ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer GlobeNewswire
Jan-08-18 08:30AM  ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer GlobeNewswire
Jan-06-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-04-18 12:11PM  Here's Why ChemoCentryx Rose as Much as 53.5% Today Motley Fool +39.42%
07:05AM  ChemoCentryx Secures up to $100 Million in New Capital Commitments GlobeNewswire
07:00AM  Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency GlobeNewswire
01:00AM  AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY GlobeNewswire
Jan-03-18 08:30AM  ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:55AM  ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017 Capital Cube +6.49%
Dec-27-17 08:41AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Nov-27-17 05:30PM  Should You Buy ChemoCentryx Inc (CCXI) Now? Simply Wall St.
Nov-18-17 08:56AM  Edited Transcript of CCXI earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-17-17 08:30AM  ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-10-17 01:06PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : November 10, 2017 Capital Cube
Nov-09-17 12:18PM  ETFs with exposure to ChemoCentryx, Inc. : November 9, 2017 Capital Cube
07:20AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : November 9, 2017 Capital Cube
Nov-07-17 05:49PM  ChemoCentryx reports 3Q loss Associated Press
04:40PM  ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Nov-03-17 08:31AM  Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
Nov-01-17 08:30AM  ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017 GlobeNewswire
Oct-20-17 08:26AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : October 20, 2017 Capital Cube
Oct-16-17 09:49AM  ETFs with exposure to ChemoCentryx, Inc. : October 16, 2017 Capital Cube
Oct-05-17 10:55AM  ETFs with exposure to ChemoCentryx, Inc. : October 5, 2017 Capital Cube
Oct-04-17 09:21AM  ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube
Oct-03-17 08:14AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : October 3, 2017 Capital Cube
Oct-02-17 05:27PM  All You Need To Know About ChemoCentryx Incs (CCXI) Risks Simply Wall St. +6.87%
Sep-15-17 08:37PM  Is There Now An Opportunity In ChemoCentryx Inc (CCXI)? Simply Wall St.
Sep-05-17 08:30AM  ChemoCentryx to Present at Three Upcoming Investor Conferences GlobeNewswire
Aug-21-17 05:55PM  ChemoCentryx, Inc. Value Analysis (NASDAQ:CCXI) : August 21, 2017 Capital Cube
Aug-14-17 02:11AM  Edited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:38AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017 Capital Cube -5.61%
01:07AM  ChemoCentryx reports 2Q loss Associated Press
Aug-08-17 04:05PM  ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
01:10PM  Investor Network: Chemocentryx, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 08:30AM  ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017 GlobeNewswire
Jul-18-17 07:29AM  New Strong Buy Stocks for July 18th Zacks
Jul-12-17 08:15AM  ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4% Zacks +5.18%
Jun-15-17 01:27PM  ETFs with exposure to ChemoCentryx, Inc. : June 15, 2017 Capital Cube
Jun-08-17 08:07AM  ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : June 8, 2017 Capital Cube
Jun-06-17 07:30AM  Oral Presentations at ERA-EDTA Congress Highlight Fourth Potential Indication for Avacopan and Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire
May-24-17 08:30AM  ChemoCentryx to Present at Two Upcoming Investor Conferences GlobeNewswire
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schall Thomas J.President and CEONov 07Option Exercise6.007,21143,2662,192,205Nov 09 06:39 PM
Schall Thomas J.President and CEONov 07Sale12.007,21186,5542,184,994Nov 09 06:39 PM
Cappel Markus J.Chief Bus. Officer & TreasurerOct 26Option Exercise6.0030,237181,42254,063Oct 30 06:47 PM
Cappel Markus J.Chief Bus. Officer & TreasurerOct 26Sale11.0130,237332,77923,826Oct 30 06:47 PM
KANAYA SUSAN MEVP, CFO and Sec.Oct 20Option Exercise0.0033,333071,468Oct 23 06:18 PM
GLAXOSMITHKLINE PLCFormer 10% holderOct 16Sale11.697,343,49285,845,4210Oct 18 05:03 PM
Edwards Thomas A.DirectorJul 28Option Exercise0.006,7670153,973Jul 31 06:50 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 29Option Exercise3.5710035738,235Jul 03 06:51 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 29Option Exercise6.0010060023,926Jun 29 07:36 PM
Schall Thomas J.President and CEOJun 29Option Exercise6.001006002,185,094Jul 02 08:20 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 29Sale14.101001,41023,826Jun 29 07:36 PM
Schall Thomas J.President and CEOJun 29Sale14.101001,4102,184,994Jul 02 08:20 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 29Sale14.101001,41038,135Jul 03 06:51 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 28Option Exercise5.6649,507280,01580,635Jun 28 07:10 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 28Option Exercise6.0024,279145,67448,105Jun 29 07:36 PM
Schall Thomas J.President and CEOJun 28Option Exercise6.0010,75764,5422,195,751Jul 02 08:20 PM
Schall Thomas J.President and CEOJun 28Sale14.0010,757150,6182,184,994Jul 02 08:20 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 28Sale13.6724,279331,99123,826Jun 29 07:36 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 28Sale13.7949,507682,49638,135Jun 28 07:10 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 27Option Exercise6.0049,150294,90087,285Jun 28 07:10 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 27Option Exercise6.008004,80024,626Jun 29 07:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJun 27Sale13.5080010,80023,826Jun 29 07:36 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 27Sale13.2549,150651,23838,135Jun 28 07:10 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 26Option Exercise6.008505,10038,985Jun 28 07:10 PM
KANAYA SUSAN MEVP, CFO and Sec.Jun 26Sale13.2585011,26338,135Jun 28 07:10 PM
Parker Geoffrey M.DirectorMay 25Option Exercise0.0012,912058,583May 30 05:13 PM
Schall Thomas J.President and CEOMay 23Option Exercise6.0027,928167,5682,212,922May 23 09:53 PM
Schall Thomas J.President and CEOMay 23Sale13.0127,928363,2932,184,994May 23 09:53 PM
Schall Thomas J.President and CEOMay 22Option Exercise6.0030,932185,5922,215,926May 23 09:53 PM
Schall Thomas J.President and CEOMay 22Sale13.0030,932402,1502,184,994May 23 09:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Option Exercise6.002,70916,25426,535May 23 09:52 PM
Schall Thomas J.President and CEOMay 21Option Exercise6.0033,938203,6282,218,932May 23 09:53 PM
Schall Thomas J.President and CEOMay 21Sale12.5533,938426,0222,184,994May 23 09:53 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 21Sale13.002,70935,21723,826May 23 09:52 PM
Schall Thomas J.President and CEOMay 17Option Exercise6.0017,798106,7882,202,792May 17 07:38 PM
Schall Thomas J.President and CEOMay 17Sale12.1417,798216,1372,184,994May 17 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 16Option Exercise6.0050,000300,00057,160May 17 07:34 PM
Schall Thomas J.President and CEOMay 16Option Exercise6.0082,202493,2122,267,196May 17 07:38 PM
Schall Thomas J.President and CEOMay 16Sale12.2682,2021,007,6652,184,994May 17 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 16Sale11.8150,000590,63723,826May 17 07:34 PM
KANAYA SUSAN MEVP, CFO and Sec.May 15Option Exercise6.008,30649,83646,441May 17 07:29 PM
Schall Thomas J.President and CEOMay 15Option Exercise6.00100,000600,0002,284,994May 17 07:38 PM
Schall Thomas J.President and CEOMay 15Sale11.32100,0001,132,0602,184,994May 17 07:38 PM
KANAYA SUSAN MEVP, CFO and Sec.May 15Sale11.148,30692,52638,135May 17 07:29 PM
KANAYA SUSAN MEVP, CFO and Sec.May 08Option Exercise6.0065,328391,968103,463May 10 07:05 PM
KANAYA SUSAN MEVP, CFO and Sec.May 08Sale11.5365,328752,92538,135May 10 07:05 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 02Option Exercise6.0038,089228,53461,915May 03 08:29 PM
KANAYA SUSAN MEVP, CFO and Sec.May 02Option Exercise6.001,3668,19639,501May 04 05:36 PM
Schall Thomas J.President and CEOMay 02Option Exercise6.0032,873197,2382,217,867May 03 08:38 PM
Schall Thomas J.President and CEOMay 02Sale11.0332,873362,4512,184,994May 03 08:38 PM
KANAYA SUSAN MEVP, CFO and Sec.May 02Sale11.501,36615,70938,135May 04 05:36 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 02Sale11.0238,089419,88623,826May 03 08:29 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 01Option Exercise6.0011,91171,46635,737May 03 08:29 PM
Schall Thomas J.President and CEOMay 01Option Exercise6.0017,127102,7622,202,121May 03 08:38 PM
Schall Thomas J.President and CEOMay 01Sale11.0017,127188,4072,184,994May 03 08:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerMay 01Sale11.0011,911131,02723,826May 03 08:29 PM
Schall Thomas J.President and CEOJan 01Option Exercise0.0066,66602,221,711Jan 03 07:47 PM
KANAYA SUSAN MEVP, CFO and Sec.Jan 01Option Exercise0.0033,333057,184Jan 03 07:38 PM
Cappel Markus J.Chief Bus. Officer & TreasurerJan 01Option Exercise0.0018,333034,724Jan 03 07:31 PM
SINGH RAJINDERSVP, ResearchJan 01Option Exercise0.0010,000010,000Jan 03 07:24 PM